1
|
Ollikainen RK, Kotkaranta PH, Kemppainen J, Teppo HR, Kuitunen H, Pirinen R, Turpeenniemi-Hujanen T, Kuittinen O, Kuusisto MEL. Different chemokine profile between systemic and testicular diffuse large B-cell lymphoma. Leuk Lymphoma 2021; 62:2151-2160. [PMID: 33856274 DOI: 10.1080/10428194.2021.1913150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Although treatment for diffuse large B-cell lymphoma (DLBCL) has taken some notable steps in the 2000s, there are still subgroups of patients suffering from high mortality and relapse rates. To further improve treatment outcomes, it is essential to discover new mechanisms of chemotherapy resistance and create new treatment approaches to overcome them. In the present study, we analyzed the expression of chemokines and their ligands in systemic and testicular DLBCL. From our biopsy sample set of 21 testicular and 28 systemic lymphomas, we were able to demonstrate chemokine profile differences and identify associations with clinical risk factors. High cytoplasmic CXCL13 expression had correlations with better treatment response, lower disease-related mortality, and limited stage. This study suggests that active CXCR5/CXCL13 signaling could overtake the CXCR4/CXCL12 axis, resulting in a better prognosis.
Collapse
Affiliation(s)
- Riina K Ollikainen
- Cancer and Translational Medicine Research Unit, University of Oulu, Oulu, Finland.,Department of Oncology and Radiotherapy and Medical Research Center, Oulu University Hospital, Oulu, Finland
| | - Pyry H Kotkaranta
- Cancer and Translational Medicine Research Unit, University of Oulu, Oulu, Finland.,Department of Oncology and Radiotherapy and Medical Research Center, Oulu University Hospital, Oulu, Finland
| | - Janette Kemppainen
- Cancer and Translational Medicine Research Unit, University of Oulu, Oulu, Finland.,Department of Oncology and Radiotherapy and Medical Research Center, Oulu University Hospital, Oulu, Finland
| | - Hanna-Riikka Teppo
- Cancer and Translational Medicine Research Unit, University of Oulu, Oulu, Finland.,Department of Oncology and Radiotherapy and Medical Research Center, Oulu University Hospital, Oulu, Finland.,Department of Pathology, Oulu University Hospital, Oulu, Finland
| | - Hanne Kuitunen
- Department of Oncology and Radiotherapy and Medical Research Center, Oulu University Hospital, Oulu, Finland
| | - Risto Pirinen
- Department of Pathology, North Karelia Central Hospital, Joensuu, Finland
| | - Taina Turpeenniemi-Hujanen
- Cancer and Translational Medicine Research Unit, University of Oulu, Oulu, Finland.,Department of Oncology and Radiotherapy and Medical Research Center, Oulu University Hospital, Oulu, Finland
| | - Outi Kuittinen
- Department of Oncology and Radiotherapy and Medical Research Center, Oulu University Hospital, Oulu, Finland.,Department of Oncology, Faculty of Health Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland
| | - Milla E L Kuusisto
- Cancer and Translational Medicine Research Unit, University of Oulu, Oulu, Finland.,Department of Oncology and Radiotherapy and Medical Research Center, Oulu University Hospital, Oulu, Finland.,Department of Hematology, Oulu University Hospital, Oulu, Finland
| |
Collapse
|